idecabtagene vicleucel (Abecma)
Jump to navigation
Jump to search
Indications
- treatment of multiple myeloma after 4 or more prior lines of therapy
Dosage
- 300-460 million CAR-positive T cells
* 100 mL 4,600,000 cells/mL injection
* 70 mL 6,571,428 cells/mL injection
* 30 mL 15,333,333 cells/mL injection
Adverse effects
- most common
- cytokine release syndrome
- neurologic toxicities
- hemophagocytic lymphohistiocytosis/macrophage activation syndrome
- prolonged cytopenias
Mechanism of action
- cell-based gene therapy
- B-cell maturation antigen-directed genetically modified autologous CAR T-cell therapy
More general terms
References
- ↑ FDA Drug Approvals. March 26, 2021 FDA approves idecabtagene vicleucel for multiple myeloma https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-idecabtagene-vicleucel-multiple-myeloma
- ↑ Nelson R 'Phenomenal' Results with CAR T-Cells in R/R Multiple Myeloma. Medscape. March 2, 2021 https://www.medscape.com/viewarticle/946733
- ↑ ABECMA HIGHLIGHTS OF PRESCRIBING INFORMATION https://www.fda.gov/media/147055/download